Canaccord Genuity analyst Max Masucci maintained a Buy rating on Guardant Health (NASDAQ:GH) on Friday, setting a price target of $125, which is approximately 6.46% above the present share price of $117.42.
Masucci expects Guardant Health to post earnings per share (EPS) of -$0.57 for the fourth quarter of 2020.
The current consensus among 2 TipRanks analysts is for a Moderate Buy rating of shares in Guardant Health, with an average price target of $117.5.
The analysts price targets range from a high of $125 to a low of $110.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $66.34 million and a net profit of -$54.62 million. The company's market cap is $11.7 billion.
According to TipRanks.com, Canaccord Genuity analyst Max Masucci is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 53.9% and a 77.59% success rate.
Guardant Health, Inc. is a precision oncology company, which engages in provision of precision oncology testing and development services. It focuses performing blood tests, vast data sets, and advanced analytics to conquer cancer. The company was founded by Helmy Eltoukhy and AmirAli H. Talasaz in 2012 and is headquartered in Redwood (NYSE:RWT) City, CA.